Ist eine D2- gegenüber einer D1-Lymphknotendissektion für Patienten mit Magenkarzinom von Vorteil?

Maruyama K, Okabayashi K, Kinoshita T (1987) Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11:418–425PubMedCrossRefGoogle Scholar

Bonenkamp JJ, Songun I, Hermans J et al (1995) Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345:745–748PubMedCrossRefGoogle Scholar

Cuschieri A, Fayers P, Fielding J et al (1996) Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347:995–999PubMedCrossRefGoogle Scholar

Degiuli M, Sasako M, Ponti A et al (2014) Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 101:23–31PubMedCrossRefGoogle Scholar

Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRefGoogle Scholar

Wu CW, Hsiung CA, Lo SS et al (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7:309–315PubMedCrossRefGoogle Scholar